Company intelligence / Profile preview

PLURI'ailes

Ownership: Private
Employees: ~180
Development stage: Commercial

Overview

Pluri has advanced proprietary technology for scalable 3D expansion of human cells. Its lead programs include a placenta-derived MAIT cell platform for solid tumor immunotherapy and PLXR18 (avoplacel) for acute radiation syndrome and hematopoietic recovery. The company’s technologies are validated in late-stage clinical trials with regulatory engagement across the US FDA, EMA, Israel MOH, Japan PMDA, and Korea MFDS. Orphan drug designations have been granted by the FDA.

Therapeutic areas: OncologyHematology
Modalities: Cell therapyInduced pluripotent stem cell derived therapyExosome-based therapyImmunotherapyMesenchymal stem cell therapy
Industry: Biotech

Partnerships

Remedy Cell – manufacturing partnership for idiopathic pulmonary fibrosis treatment RC‑0315NIH & US Department of Defense – development partnership on PLXR18/avoplacel

Beyond the preview

Go deeper on PLURI'ailes.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PLURI'ailes.

Explore the full profile